Evidence map›Paper›PMID 27224245›Full record

ArticlePloS one2016

Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis.

Nada Abdelmagid, Biborka Bereczky-Veress, Santosh Atanur, Alena Musilová, Václav Zídek, Laura Saba, Andreas Warnecke, Mohsen Khademi, Marie Studahl, Elisabeth Aurelius and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 6 countries.

Nada AbdelmagidDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.ORCID 0000-0002-8200-347X
Biborka Bereczky-VeressDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Santosh AtanurDivision of Medicine, Imperial College London, London, United Kingdom.
Alena MusilováInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Václav ZídekInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Laura SabaDepartment of Pharmacology, University of Colorado, Denver School of Medicine, Denver, United States of America.
Andreas WarneckeDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Mohsen KhademiDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Marie StudahlDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Elisabeth AureliusDepartment of Medicine, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Anders HjalmarssonDepartment of Medicine, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Ana Garcia-DiazDivision of Medicine, Imperial College London, London, United Kingdom.
Cécile V DenisInstitut National de la Santé et de la Recherche Médicale UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.
Tomas BergströmDepartment of Clinical Virology, University of Gothenburg, SE-413 46 Gothenburg, Sweden.
Birgit SköldenbergDepartment of Medicine, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Ingrid KockumDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Timothy AitmanDivision of Medicine, Imperial College London, London, United Kingdom.
Norbert HübnerMax-Delbruck-Center for Molecular Medicine, Berlin-Buch, Berlin, Germany.
Tomas OlssonDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Michal PravenecInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Margarita DiezDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Karolinska University Hospital · SECzech Academy of Sciences · CZImperial College London · GBUniversity of Gothenburg · SEMax Delbrück Center · DEUniversité Paris-Sud · FRUniversity of Colorado Denver · US

Funding

The Heritable Transcriptome and AlcoholismR24AA013162 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI HOFFMAN, PAULA, SABA, LAURA MAREN · 2001 to 2021
$14.2M
Gene Array Technology Center for Alcohol ResearchR01AA013162 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI TABAKOFF, BORIS · 2002 to 2005
$5.8M
Colorado Gene Array CoreU01AA016663 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI TABAKOFF, BORIS · 2006 to 2010
$2.2M
Medical Research Council MC_U120061454NIAAA NIH HHS R01 AA013162NIAAA NIH HHS R24 AA013162NIAAA NIH HHS U01 AA016663
6 · The paper itself

Abstract

Herpes simplex encephalitis (HSE) is a rare complication of Herpes simplex virus type-1 infection. It results in severe parenchymal damage in the brain. Although viral latency in neurons is very common in the population, it remains unclear why certain individuals develop HSE. Here we explore potential host genetic variants predisposing to HSE. In order to investigate this we used a rat HSE model comparing the HSE susceptible SHR (Spontaneously Hypertensive Rats) with the asymptomatic infection of BN (Brown Norway). Notably, both strains have HSV-1 spread to the CNS at four days after infection. A genome wide linkage analysis of 29 infected HXB/BXH RILs (recombinant inbred lines-generated from the prior two strains), displayed variable susceptibility to HSE enabling the definition of a significant QTL (quantitative trait locus) named Hse6 towards the end of chromosome 4 (160.89-174Mb) containing the Vwf (von Willebrand factor) gene. This was the only gene in the QTL with both cis-regulation in the brain and included several non-synonymous SNPs (single nucleotide polymorphism). Intriguingly, in human chromosome 12 several SNPs within the intronic region between exon 43 and 44 of the VWF gene were associated with human HSE pathogenesis. In particular, rs917859 is nominally associated with an odds ratio of 1.5 (95% CI 1.11-2.02; p-value = 0.008) after genotyping in 115 HSE cases and 428 controls. Although there are possibly several genetic and environmental factors involved in development of HSE, our study identifies variants of the VWF gene as candidates for susceptibility in experimental and human HSE.

Indexed as

Herpesvirus 1, HumanPolymorphism, Single NucleotideQuantitative Trait, HeritableAnimalsChromosomes, MammalianEncephalitis, Herpes SimplexGenotyping TechniquesHumansRatsRats, Inbred SHRvon Willebrand Factorvon Willebrand Factor

Identifiers

PMID27224245
PMCPMC4880288
OpenAlexW2404571546

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.